Japanese launch of ActHIB delayed
This article was originally published in Scrip
Manufacturing issues have delayed the Japanese launch of Sanofi Pasteur-Daiichi Sankyo Vaccines' paediatric meningitis vaccine ActHIB. The Haemophilus influenzae type b prophylactic vaccine was approved back in January 2007 and was expected to reach the market this summer. However, batch production to a standard required for the Japanese market has taken longer than expected, the Japanese joint venture said. A December launch following the import of an increased quantity from Sanofi Pasteur in France is now planned, although a final date has not been fixed. Daiichi Sankyo will distribute the product, which is not currently eligible for reimbursement under Japan's national insurance system.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.